Cancer News and Research

Latest Cancer News and Research

Researchers aim to over-stress already taxed mantle cell lymphoma cells

Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them.

11 Nov 2008

National call for cancer trial system to be more responsive to community needs

Addressing the nation's continuing poor performance in cancer clinical trial participation, particularly among racial and ethnic minorities and low income groups, will require meaningful public involvement in the design and implementation of clinical trials, according to a landmark report released today.

11 Nov 2008

Struggling with incontinence? seek help

More than 15 million Americans, primarily women, suffer from incontinence.

11 Nov 2008

Cancer risk from cardiac CT overstated

Radiology and cardiovascular researchers from the Medical University of South Carolina in Charleston, S.C., today presented new data that shows the risk of cancer from exposure to radiation during computed tomography for cardiovascular disease has been overstated and that new estimates are several times lower than previously published conclusions.

10 Nov 2008

Ewing sarcoma treatment ineffective, despite promising laboratory data

Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults.

10 Nov 2008

Flu shots cut the risk of blood clots forming in veins

According to new research by French scientists flu shots may reduce the risk of venous thrombotic embolism.

10 Nov 2008

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

Twins born from 13-year-old frozen sperm

Reports from Taiwan say the sperm taken from a man with testicular cancer 13 years ago has been successfully used to impregnate his wife.

10 Nov 2008

Cancer study a world first

A research study to recruit foreign language speaking cancer patients through Australian Cancer Registries will begin in New South Wales this month.

10 Nov 2008

Chaotic vasculature hinders tumor growth

Dense networks of blood vessels thought to spur cancer's growth could actually hinder rather than promote tumor progression, according to a new study at the University of California, San Diego.

10 Nov 2008

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.

10 Nov 2008

Scientists engineer immune cells to act as "bionic assassins" that see through HIV's many disguises

HIV is a master of disguise, able to rapidly change its identity and hide undetected in infected cells.

10 Nov 2008

New hybrid technology for disease prevention

The earlier cancer is diagnosed, the better the chance of effecting a cure.

10 Nov 2008

Flu shots may reduce risk of blood clots forming in veins

Flu shots may reduce the risk of blood clots forming in veins by 26 percent, according to research presented at the American Heart Association's Scientific Sessions 2008.

10 Nov 2008

Scientists engineer T cells to recognize HIV-1 strains that have evaded the immune system

The findings of the study, published online in the journal Nature Medicine, have important implications for developing new treatments for HIV, especially for patients with chronic infection who fail to respond to antiretroviral regimens.

10 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008